drugset / Trial / NCT02478840

Evaluation of Long-term Efficacy of Treatment With Lamazym

NCT02478840 ↗

Phase 3 Completed 18 enrolled Zymenex A/S
NaSingle-groupOpen-labelTreatment

Summary

The overall objective is to evaluate the long-term efficacy of Lamazym i.v. treatment in patients with alpha-Mannosidosis previously enrolled in Lamazym trials and currently receiving the treatment according to the AfterCare Program.

Timeline

Start
2015-02
Primary completion
2015-06
Completion
2015-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Velmanase Alfa Protein / enzyme biologic 1 mg/kg Intravenous

Indications